2月13日,BMS宣布III期RELATIVITY-098研究未能达到主要终点——无复发生存期(RFS)。该研究旨在评估Opdualag(纳武利尤单抗+瑞拉利单抗)与Opdivo(纳武利尤单抗)单药治疗相比,针对完全切除的III期至IV期黑色素瘤患者进行辅助免疫治疗的疗效和安全性。Opdualag是首个获得批准的PD-1+LAG-3组合抗体疗法,2022年3月,FDA批准该药用于治疗患有不可切除或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.